Perilla seed oil as an adjunctive treatment with a statin improves lipid profiles in elderly: a post hoc data analysis.
- Conditions
- Dyslipidemia in mild to moderate dementia patients.Perilla seed oil, Statin, Lipid level, Dementia
- Registration Number
- TCTR20230913003
- Lead Sponsor
- Center of Excellence in Stroke, Thammasat University
- Brief Summary
In summary, perilla seed oil, particularly when combined with statin therapy, is promising for improving lipid profiles and might offer liver protection. While its omega-3 content and beneficial compounds are valuable, further research, including long-term studies, is needed to fully validate its clinical benefits in treating cardiovascular disease and related concerns.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- All
- Target Recruitment
- 182
The patients were 50-90 years old and gained 10-23 scores measured by the Thai Mental State Examination (TMSE) or 7-20 scores measured by the Thai Montreal Cognitive Assessment (MoCA-Thai). They suffered from mild to moderate dementia based on the Diagnosis and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV). They could recognize and communicate and gave written informed consent.
They were found to have creatinine greater than 2 mg/dL on the recruitment day. Their laboratory results showed 2.5 times greater abnormal liver function than the upper normal limit. The patients had treatable causes of dementia, such as vitamin B12 deficiency, hypothyroidism, normal pressure hydrocephalus, and neuro-syphilis. They had bleeding disorders. They were receiving warfarin or taking supplements. They suffered from major depression. They were allergic to medicinal and herbal medicines.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method lipid profile Baseline, 3 month, and 6 month post-dose Low Density Lipoprotein ,lipid profile Baseline, 3 month, and 6 month post-dose High Density Lipoprotein,lipid profile Baseline, 3 month, and 6 month post-dose Triglyceride,lipid profile Baseline, 3 month, and 6 month post-dose Total cholesterol,lipid profile Baseline, 3 month, and 6 month post-dose Low Density Lipoprotein/High Density Lipoprotein ratio
- Secondary Outcome Measures
Name Time Method Blood sugar Baseline, 3 month, and 6 month post-dose Fasting Blood Sugar,Blood sugar Baseline, 3 month, and 6 month post-dose Hemoglobin A1c ,Liver function levels Baseline, 3 month, and 6 month post-dose Serum glutamic oxaloacetic transaminase,Liver function levels Baseline, 3 month, and 6 month post-dose serum glutamic pyruvic transaminase,Renal function levels Baseline, 3 month, and 6 month post-dose Blood Urea Nitrogen,Renal function levels Baseline, 3 month, and 6 month post-dose Creatinine,Renal function levels Baseline, 3 month, and 6 month post-dose Glomerular Filtration Rate,complete blood count Baseline, 3 month, and 6 month post-dose White Blood Cell Count,complete blood count Baseline, 3 month, and 6 month post-dose Red blood cell ,complete blood count Baseline, 3 month, and 6 month post-dose Hematocrit,complete blood count Baseline, 3 month, and 6 month post-dose Neutrophil /Lymphocyte Platelet ratio